Sakar Healthcare saw a 5% jump in its stock after getting the green light from the EU for two new oncology injections Carboplatin and Docetaxel. These medications are designed to tackle ovarian and lung cancer, along with other solid tumours. With these approvals, the company now boasts a total of four EU authorisations, further strengthening its global oncology portfolio.